论文部分内容阅读
阿斯特拉公司的胃酸抑制剂奥美拉唑本周已上市,为洛赛克胶囊。这种新药以它新颖的作用,作为一个质子原抑制剂比H_2拮抗剂更有效,对溃疡有高效治愈率。该药以20mg的剂量在24hr内抑制80％的酸的释放。然而与H_2拮抗剂挑战的机会是健康卫生部已许可奥美拉唑只用于治疗习惯疗法不能治愈的溃疡,然而阿斯特拉认为这不是主要的市场,只希望此药在
Astra’s stomach acid inhibitor omeprazole has been listed this week, Losec capsule. With its novel effect, this new drug is more effective than a H 2 antagonist as a proton inhibitor and has a high cure rate for ulcers. The drug inhibits 80% acid release in 24 hr at a dose of 20 mg. However, the challenge with H 2 antagonists is that the Ministry of Health and Human Services has licensed omeprazole to treat ulcers that can not be remedied by habitual therapy, but Astra does not consider it a major market,